Optimization of systemic AAV9 gene therapy in Niemann–Pick disease, type C1 mice
Life Science Alliance · 2026
DOI: 10.26508/lsa.202402874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2026. Verfasst von Avani V Mylvara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Health and Services, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Heal…. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type C, Genetic Therapy, Dependovirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NINDS NIH HHS, HHS | NIH | National Human Genome Research Institute.
Abstract (Originalsprache)
Niemann–Pick disease, type C1 (NPC1), is a rare, fatal neurodegenerative disorder caused by pathological variants in NPC1 , which encodes a lysosomal cholesterol transporter. FDA-approved treatments are limited and do not target the underlying genetic defect. Both systemic and central nervous system delivery of AAV9-h NPC1 have shown significant disease amelioration in NPC1 murine models. To assess the impact of dose in null Npc1 m1N/m1N mice, we systemically administered three different doses of AAV9-h NPC1 at 4 wk old. Then, to assess the impact of age, we administered the medium dose before phenotypic onset or at early or late stage of disease progression (4, 6, or 8 wk old, respectively). Higher vector doses and earlier treatment were associated with significantly increased lifespan, slower disease progression, and enhanced central nervous system transduction. In Npc1 I1061T/I1061T mice, a model recapitulating a common human hypomorphic variant, similar benefits ensued. Our findings help define dose ranges, treatment ages, and efficacy in hypomorphic models of NPC1 deficiency and suggest that higher doses of AAV9-h NPC1 in presymptomatic disease states are likely to yield better outcomes in NPC1 individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Human Health and Services, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
- Department of Human Health and Services, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
- Howard Hughes Medical Institute, Department of Cellular and Molecular Medicine, Section of Neurobiology, Division of Biological Sciences, University of California San Diego, San Diego, CA, USA.
- University of North Carolina, Chapel Hill, NC, USA.
- Department of Human Health and Services, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA cristin.davidson@nih.gov.
- University of Illinois Chicago, Chicago, IL, USA.
ORCID-Profile: Avani V Mylvara, Alana L Gibson, Tansy Gu, Cristin D Davidson, Arturo A Incao, Katerina Melnyk, Dominick Pierre-Jacques, Stephanie M Cologna, Charles P Venditti, Forbes D Porter, William J Pavan
Förderung
- Intramural NIH HHS
- NINDS NIH HHS
- HHS | NIH | National Human Genome Research Institute
- HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development
- HHS | National Institutes of Health
- Ara Parseghian Medical Research Fund
Zitieren
APA
Mylvara, A. V., Gibson, A. L., Gu, T., Davidson, C. D., Incao, A. A., Melnyk, K., Gembic, S. R., Pierre-Jacques, D., Cologna, S. M., Venditti, C. P., Porter, F. D., & Pavan, W. J. (2026). Optimization of systemic AAV9 gene therapy in Niemann–Pick disease, type C1 mice. Life Science Alliance. https://doi.org/10.26508/lsa.202402874
Vancouver
Mylvara AV, Gibson AL, Gu T, Davidson CD, Incao AA, Melnyk K, et al. Optimization of systemic AAV9 gene therapy in Niemann–Pick disease, type C1 mice. Life Science Alliance. 2026. doi:10.26508/lsa.202402874
BibTeX
@article{Mylvara2026,
author = {Mylvara, Avani V and Gibson, Alana L and Gu, Tansy and Davidson, Cristin D and Incao, Arturo A and Melnyk, Katerina and Gembic, Susan R and Pierre-Jacques, Dominick and Cologna, Stephanie M and Venditti, Charles P and Porter, Forbes D and Pavan, William J},
title = {Optimization of systemic AAV9 gene therapy in Niemann–Pick disease, type C1 mice},
journal = {Life Science Alliance},
year = {2026},
doi = {10.26508/lsa.202402874}
}
EUVIMED